Search

Displaying results 7331 - 7340 of 7555 in total
  1. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  2. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others. Tosedostat is an inhibitor of the M1 family of aminopeptidases, in pa...

  3. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  4. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  5. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    Telcagepant has been investigated for the treatment of Migraine. It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors a...

  6. Drug

    Amibegron

    go.drugbank.com/drugs/DB05395
    Investigational

    Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.

  7. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  8. Drug

    NPI 32101

    go.drugbank.com/drugs/DB05264
    Experimental

    NPI 32101 possesses both anti-inflammatory and broad spectrum antimicrobial activities. This combination of pharmacological properties may have additional therapeutic uses beyond dermatology.

  9. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    CG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  10. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been disc...